Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain, Neurodegeneration, and CNS Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SSTR4 (Somatostatin Receptor 4) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SSTR4 Mutant / Fragment Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SSTR4 Products |
| Cell Line | SSTR4 Overexpression Stable Cell Line HEK293 Expressed, Surface Expression Verified by Flow Cytometry, Sequence Verified. |
View SSTR4 Products |
| Gene Delivery | SSTR4 Premade Lentivirus Particles Full-length ORF, High Titer (>10^8 TU/mL), Puromycin Selection, Endotoxin Controlled. |
View SSTR4 Products |
| Benchmark Ab | Anti-SSTR4 Reference Antibody Sequence Verified, Flow Cytometry Validated for Cell Surface Binding. |
View SSTR4 Products |
| Validator | SSTR4 siRNA Set (3 Unique Targets) For Knockdown Verification, High Transfection Efficiency. |
View SSTR4 Products |
| Related Target A | SSTR2 (Somatostatin Receptor 2) Primary target for NETs; Critical for selectivity screening vs. SSTR4. |
View SSTR2 Products |
| Related Target B | SSTR1 (Somatostatin Receptor 1) Additional family member for selectivity profiling. |
View SSTR1 Products |
| Related Target C | SSTR5 (Somatostatin Receptor 5) Co-expressed in pituitary; Relevant for endocrine safety profiling. |
View SSTR5 Products |
| Related Target D | GHSR (Growth Hormone Secretagogue Receptor) Functional antagonist in growth hormone regulation; CNS indication synergy. |
View GHSR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity & Glycosylation | Lentivirus-generated stable cell lines preserving native membrane architecture; HEK293 expressed with mammalian glycosylation patterns. |
| SSTR Subfamily Selectivity (SSTR2 vs SSTR4) | Human/Mouse/Cyno Ortholog Panel for SSTR1/2/3/4/5; Sequence Verified for precise off-target profiling. |
| Gai/o Signaling Detection (Inhibitory) | Compatible with Chimeric G-Protein (Gqi5/Gqo5) Cell Lines for Calcium Flux Conversion; High Surface Expression Guaranteed. |
| Receptor Internalization/Trafficking | Live Cell Imaging Compatible Cell Lines; siRNA Controls for Specificity Validation included. |
| Lack of Reliable Controls | Sequence-verified benchmark antibodies included as functional positive controls. |
| False Positives in Cell Assays | Validated siRNA included for specificity and baseline checks. |
Live SSTR4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SSTR4 therapeutics is intensifying as developers seek novel, non-opioid targets for neuropathic pain, inflammation, and CNS disorders. Unlike other somatostatin receptors, SSTR4 activation does not inhibit growth hormone release, making it an ideal target for chronic conditions. Major players are shifting focus from traditional SSTR2-targeted NET therapies to selective SSTR4 modulation. As first-generation small molecule agonists advance, the next wave of R&D is targeting biased agonists that selectively activate G-protein signaling over β-arrestin recruitment, aiming to maximize analgesic and anxiolytic effects while minimizing endocrine disruption. Additionally, SSTR4's role in amyloid-beta clearance has opened new possibilities for Alzheimer's disease treatment. Emerging indications include depression, anxiety, and inflammatory bowel disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Agonist | Eli Lilly, Boehringer Ingelheim, Crinetics, Academic Consortia | Neuropathic Pain, Depression, Anxiety, Chronic Pain | Selectivity Assay (Need SSTR1-5 Ortholog Panel); cAMP Inhibition & Calcium Flux Ready Cell Lines |
| Targeted Degraders | Emerging Biotechs | Neurodegeneration | Internalization/Degradation (Need high-purity stable cell lines) |
| Biased Agonist (G-protein) | Early Biotech | Alzheimer's Disease, Neuroprotection | Arrestin Recruitment (bRET) vs. cAMP Differential Screening; High Expression Cell Lines for Signal Detection |
| Monoclonal Antibodies | Academic/Early Biotech | Inflammation | Binding Assays (Sequence verified antigens) |
| Peptide/Analog Conjugates | Specialized Biotech | Inflammatory Bowel Disease (IBD) | Internalization Assay (for payload delivery); Stable Cell Line with Verified Surface Density |